• Making Money Without the Speculation Rush Friday, 24 Feb 2012 | 5:32 PM ET

    Speculation has its place, but Cramer's researcher thinks there is lots of opportunity to profit from established companies, too.

  • Six out of the 10 patients treated for hepatitis C with a combination of Gilead Science’s experimental drug GS-7977 relapsed, the company disclosed Friday. “This is just par for the course. There’s a reason people do trials on their drugs. You don't know what the answer is until you get the data,” said ISI analyst Mark Schoenebaum, who has a “buy” rating on Gilead.

  • Investors Crushin' on Rare Diseases     Tuesday, 14 Feb 2012 | 2:15 PM ET

    CNBC's Seema Moody reports on heightened interest in treating rare diseases as more patents expire. BioMarin Pharmaceutical is one of the leaders in this space, and its CEO Jean-Jacques Biename, weighs in.

  • Idenix CEO on Hep C Drug Study     Tuesday, 14 Feb 2012 | 8:16 AM ET

    Insight on the FDA clearing Idenix to resume study of its advanced experimental hepatitis C drug, with Ronald Renaud, Idenix president/CEO.

  • 6 Stocks Unworthy of Biotech Bull Market Wednesday, 8 Feb 2012 | 10:57 AM ET

    Investors are riding a wave of unprecedented optimism following what seems like an avalanche of biotech deals, early drug approvals, and positive clinical news that has kicked off the year. TheStreet.com reports.

  • Cramer Slaps a ‘Buy’ on Biogen Friday, 27 Jan 2012 | 9:02 PM ET

    Find out why he’s bullish on this biotech name.

  • Cramer: Biogen Idec's Profit Pipeline     Thursday, 26 Jan 2012 | 6:25 PM ET

    Mad Money's Cramer, takes a look at Biogen Idec's medical breakthrough drugs and its near-term catalysts for growth this year.

  • Finerman's Fine Print: Roche Hostility     Wednesday, 25 Jan 2012 | 5:18 PM ET

    Fast Money trader Karen Finerman explains what's behind Roche's tender offer for Illumina; and the best way to play the biotech takeout trend.

  • Biotech Buyouts & Deal Flows     Friday, 20 Jan 2012 | 4:25 PM ET

    The biotech industry is off to its best start in over a decade. What's driving the accelerated growth? CNBC's Seema Mody has the details on speculative buyout targets this year.

  • Cramer's Speculative Biotech Play: Regeneron     Tuesday, 10 Jan 2012 | 6:15 PM ET

    Len Schleifer, Regeneron Pharmaceuticals CEO, discusses smart biotech investing and growth prospects in the company's pipeline, with Mad Money's Jim Cramer.

  • SGEN's Adcetris Targets Lymphomas     Tuesday, 10 Jan 2012 | 5:34 PM ET

    Clay Siegall, Seattle Genetics president & CEO, discusses the company's cancer drug, Adcetris, and which new drugs are in the company's pipeline for 2012.

  • Vertex & Biogen CEOs Talk Business     Tuesday, 10 Jan 2012 | 4:38 PM ET

    Jeffrey Leiden, Vertex Incoming CEO, and George Scangos, Biogen Idec CEO, discuss Biogen's restructuring and Vertex's Hepatitis C drug.

  • Which Biotech Company Is the Next Takeover Target? Monday, 9 Jan 2012 | 5:52 PM ET

    As the JPMorgan Health Care conference kicks off this week, one question remains for investors in the biotech space. What’s the next takeover target as large drug makers look to build out their pipeline?

  • Health Care & the State of Biotech     Monday, 9 Jan 2012 | 5:19 PM ET

    Richard Pops, Alkermes chairman & CEO, discusses the challenges facing the health care industry; FDA approval of a once weekly diabetes drug, and other promising new drug candidates.

  • 2011 Top Stocks: No. 5 Biogen Idec Wednesday, 28 Dec 2011 | 2:59 PM ET

    The No. 5 performer in the top S&P stocks of 2011 could see more growth ahead, one “Fast Money” pro said.

  • Fab Four: Biotech Stocks in 2012     Wednesday, 21 Dec 2011 | 1:44 PM ET

    The biotech sector has surged more than 9% in 2011, so what should investors expect for the new year? Chris Raymond, Robert W. Baird senior biotech analyst, and Karen Anderson, Morningstar senior equity analyst share insight into the sector.

  • Bulls Seek Major Rebound From Targacept Tuesday, 13 Dec 2011 | 6:02 AM ET

    Targacept has been exiled to the woodshed, but yesterday the buyers came back in force.

  • Questcor: A Cheap Biotech Stock Thursday, 17 Nov 2011 | 6:55 PM ET

    Cramer goes one-on-one with Questcor CEO Don Bailey to find out more about the company.

  • Biotech Down Big     Tuesday, 8 Nov 2011 | 2:35 PM ET

    Analysis on why the biotech sector is seeing a down trend, with Raghuram Selvaraju, Morgan Joseph TriArtisan senior vice-president/senior biotechnology analyst.

  • ImmunoGen CEO on New Breast Cancer Drug Monday, 26 Sep 2011 | 6:49 PM ET

    Daniel Junius talks to Cramer about the drug’s recent trial, which was good news for the company’s stock, and when the FDA could get it for approval.